AHCYP2

Across TCGA pan-cancer cohorts, AHCYP2 RNA is linked to patient survival in 26 of 34 cancer types, making it the most broadly survival-associated AHCYP2 data layer.

The strongest signal is observed in bladder urothelial carcinoma (BLCA), where higher AHCYP2 RNA is associated with better disease-free survival. In most high-consensus cancer types, elevated AHCYP2 expression acts as an unfavorable survival marker, although some lineages such as BLCA and COAD show a favorable association.

BLCA, OV, and ACC are the cancer types where AHCYP2 RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
BLCA	DFS	Median	III,IV	0.647	0.486	.003	69	view →
OV	OS	Quartile	All	0.792	0.908	<.001	58	view →
ACC	OS	Median	All	0.302	0.777	<.001	57	view →
COAD	DFS	Quartile	All	0.731	0.422	<.001	37	view →
LGG	DFS	Median	All	0.663	0.809	<.001	37	view →
UCS	OS	Tertile	IV	1.000	0.268	.033	22	view →
SARC	OS	Median	All	0.613	0.354	<.001	19	view →
CHOL	OS	Quartile	II,III,IV	0.227	0.961	.002	18	view →
MESO	DFS	Median	III,IV	0.183	0.591	.011	15	view →
LUSC	DFS	Quartile	III,IV	0.170	0.862	<.001	12	view →
KIRP	DFS	Quartile	All	1.000	0.590	.006	12	view →
KICH	OS	Median	All	0.831	1.000	.011	11	view →

Pink = unfavorable, green = favorable. Showing the 12 strongest of 26 lineages.

AHCYP2–BLCA (DFS)

Open the BLCA breakdown →